Bowel Cancer, Colorectal Cancer
Conditions
Keywords
Artesunate, Artemisinins, Antimalarial, Neoadjuvant, Pre-operative
Brief summary
This study evaluates the safety and effectiveness of pre-operative artesunate given orally once a day for 14 days prior to surgery in patients with Stage II/III colorectal cancer. Artesunate is an established antimalarial drug with an excellent safety profile, is well tolerated and affordable. A number of laboratory studies and one small pilot clinical study in patients with colorectal cancer have shown that artesunate can reduce the proliferation and growth of cancer cells. Two hundred patients diagnosed with Stage II/III operable colorectal cancer will be randomly allocated to receive oral artesunate 200mg daily or a matching placebo for 14 days prior to surgery. Patients will be followed up closely for 5 years to see if giving artesunate preoperatively reduces the risk of cancer recurring after surgery.
Detailed description
Artesunate is an established antimalarial drug belonging to the artemisinin class of drugs, has an excellent safety profile, is well tolerated and affordable. In last two decades, artemisinins have shown potent and broad anticancer properties in a range of cell lines and animal models, supporting the hypothesis that artemisinins have the potential to be an effective anti-cancer therapy. Multiple potential mechanisms of action include anti-proliferative effects through cell-cycle disruption, reactive oxygen species (ROS) -induced DNA damage, induction of apoptosis, anti-angiogenesis, immunomodulation and induced radiosensitivity. Despite a multi-modality treatment approach to colorectal cancer, 5 year overall survival does not currently exceed 60%. Neoadjuvant pre-operative therapy may be more effective at eradicating micrometastases compared to adjuvant therapy delivered following the delay and immunological stress of surgery. However current neoadjuvant chemotherapy regimens are often associated with significant side effects and may result in a delay in surgery whilst patients recover. A well tolerated, affordable, novel anticancer agent that could be given to patients whilst they wait for surgery, without causing a surgical delay due to treatment related toxicity, would have a significant clinical impact on patient care. The NeoART trial is a phase II multicentre randomised, double blind, placebo controlled trial (RCT) for patients undergoing primary surgery for Stage II/III colorectal cancers. Patients are randomised (1:1 ratio) to receive either a two week course of neoadjuvant artesunate 200mg once daily or matching placebo. Both patients and health care professionals are blinded to treatment allocation arm to minimise outcome-reporting bias. The primary endpoint of the trial is recurrence free survival two years after surgery. Secondary endpoints include 2 and 5 year overall survival, treatment related toxicity, tolerability and patient quality of life. A translational sub-study looking at predictive and prognostic biomarkers is also planned.
Interventions
DRUGArtesunate 200mg
Artesunate 200mg PO OD for 14 days prior to colorectal resection surgery
DRUGPlacebo
Matched placebo PO OD for 14 days prior to colorectal resection surgery
Sponsors
St George's, University of London
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Aged 18 or over 2. Histologically proven single primary site colorectal adenocarcinoma or high grade dysplasia plus unequivocal radiological evidence of invasive cancer 3. Stage II/III colorectal cancer planned for surgical resection and no clinical indication for neoadjuvant preoperative chemotherapy/chemoradiation therapy 4. WHO performance status 0,1 or 2 5. Adequate full blood count: White Cell Count (WCC) \>3.0 x 10\^9 /l; Platelets \>100 x 10\^9/l; Haemoglobin (Hb) \>80g/L 6. Adequate renal function: Glomerular Filtration Rate \>30ml/min by Cockcroft-Gault formula 7. Adequate hepatobiliary function : Bilirubin \< 3 x Upper limit normal 8. Female participants of child bearing potential must have a negative pregnancy test \< 72 hours prior to initiating study intervention and agree to avoid pregnancy using adequate, medically approved contraceptive precautions for up to 6 weeks after the last dose of study treatment intervention 9. Male participants with a partner of childbearing potential must agree to use adequate, medically approved contraceptive precautions during and for up to 6 weeks after the last dose of the study treatment intervention 10. Patient able and willing to provide written, informed consent for the study.
Exclusion criteria
1. Contraindication to the use of artesunate due to hypersensitivity 2. Pregnancy or lactation 3. Male or female participants unwilling to use an effective method of birth control (either hormonal in the form of contraceptive pill or barrier method of birth control accompanied by the use of a proprietary spermicidal foam/gel or film); or agreement of true abstinence from time to consent is signed until 6 weeks after the last dose of study treatment intervention (i.e. withdrawal, calendar, ovulation, symptothermal and post ovulation methods are not considered acceptable methods) 4. History of immunosuppression 5. History of hearing or balance problems 6. Weight \< 52kg or \> 110kg 7. Other planned intervention, apart from standard of care 8. Any other malignant disease diagnosis within the preceding 2 years with the exception of non-melanomatous skin cancer and carcinoma in situ 9. Lactose intolerance
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Recurrence free survival at 2 years | 2 years following study randomisation. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival at 2 and 5 years | 2 and 5 years from study randomisation | — |
| Colon cancer specific death at 2 and 5 years | 2 and 5 years from study randomisation | — |
| Number of patients experiencing artesunate drug related toxicity as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.0 | Assessment at Day 7 following start of study intervention (artesunate/matching placebo) | — |
| Adverse events affecting patients as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.0 | Assessment at Day 7 following study intervention | — |
| Pathological assessment of tumour regression (involvement of lymph nodes; serosa; resection margin) | Post surgical pathology review (following Day 14 of study intervention) | — |
| Patient quality of life | Assessment at Day 1 of study intervention | Using validated quality of life self-administered questionnaires |
| Surgical complications | From time of surgery up to 3 months post surgery | Number of patients with surgery related adverse events as assessed by CTCAE v4.0 |
| Predictive value of tumour marker Carcinoma Embryonic Antigen (CEA) kinetics in terms of predicting response to artesunate therapy | Assessment at Day 1 of study intervention | — |
| Immunohistochemical analyses of paraffin-embedded tumour sections to assess Kirsten rat sarcoma viral oncogene homolog (Kras) mutation status | Pre and post intervention tumour samples from patients (Day 0 and Day 15) | Number of patients with Kras mutant tumours |
| Recurrence free survival at 5 years | 5 years from study randomisation | — |
| Immunohistochemical analyses of paraffin-embedded tumour for v-Raf murine sarcoma viral oncogene homolog B (BRAF) mutation status | Pre and post intervention tumour samples from patients (Day 0 and Day 15) | Number of patients with BRAF mutant tumours |
| Immunohistochemical analyses of paraffin-embedded tumour for Platelet derived growth factor (PDGF) expression | Pre and post intervention tumour samples from patients (Day 0 and Day 15) | Number of patients whose tumours show PDGF upregulation/downregulation following treatment intervention |
| Immunohistochemical analyses of paraffin-embedded tumour for Platelet derived growth factor receptor (PDGFR) expression | Pre and post intervention tumour samples from patients (Day 0 and Day 15) | Number of patients whose tumours show PDGFR upregulation/downregulation following study intervention |
| Immunohistochemical analyses of paraffin-embedded tumour for Vascular endothelial Growth Factor (VEGF) expression | Pre and post intervention tumour samples from patients (Day 0 and Day 15) | Number of patients whose tumours show VEGF upregulation/downregulation following study intervention |
| Immunohistochemical analyses of paraffin-embedded tumour on Vascular endothelial Growth Factor Receptor (VEGFR) expression | Pre and post intervention tumour samples from patients (Day 0 and Day 15) | Number of patients whose tumours show VEGFR upregulation/downregulation following study intervention |
| Determination of proliferative activity (Ki-67 staining, Cluster of Differentiation 31 protein (CD31) staining) | Pre and post intervention tumour samples from patients (Day 0 and Day 15) | Number of patients whose tumours show an increase or reduction in proliferation markers Ki67 and CD31 following study intervention |
| Determination of activation of the Deoxyribonucleic acid damage response (DDR) pathway | Pre and post intervention tumour samples from patients (Day 0 and Day 15) | Number of patients whose tumour samples show activation of the DDR pathway following study intervention |
| Wnt/β-catenin proliferation pathway protein expression (e.g. c-myc and cyclinD1 proteins) | Pre and post intervention tumour samples from patients (Day 0 and Day 15) | Number of patients who show an increase or a decrease in expression of proteins involved in the Wnt/β-catenin proliferation pathway (e.g. c-myc and cyclinD1 proteins) following study intervention |
| Immunohistochemical analyses of paraffin-embedded tumour sections to assess Mismatch Repair (MMR) status | Pre and post intervention tumour samples from patients (Day 0 and Day 15) | Number of patients with Mismatch Repair (MMR) mutant tumours |
Countries
United Kingdom
Contacts
Primary ContactProfessor Sanjeev Krishna, FRCP, ScD, FMedSci
Backup ContactDr Yolanda Augustin, MBBS, MRCP, FRCR, MSc
Outcome results
None listed